SARS-CoV-2 vaccination in the first year after hematopoietic cell transplant or chimeric antigen receptor T cell therapy: A prospective, multicenter, observational study.

Joshua A HillMichael J MartensJo-Anne H YoungKavita BhavsarJianqun KouMin ChenLik Wee LeeAliyah BaluchMadhav V DhodapkarRyotaro NakamuraKristin PeytonDianna S HowardUroosa IbrahimZainab ShahidPaul ArmisteadPeter WesterveltJohn McCartyJoseph McGuirkMehdi HamadaniSusan DeWolfKinga HosszuElad SharonAshley SpahnAmir A ToorStephanie WaldvogelLee M GreenbergerJeffery J AulettaMary M HorowitzMarcie L RichesMiguel-Angel Perales

Published in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2024)

These data support mRNA SARS-CoV-2 vaccination prior to, and reinitiation three to four months after, cellular therapies with allogeneic HCT, autologous HCT, and CAR-T cell therapy.

Keyphrases

cell therapy
sars cov
bone marrow
mesenchymal stem cells
respiratory syndrome coronavirus
stem cells
stem cell transplantation
cell cycle arrest
electronic health record
cross sectional
big data
cell death
double blind
machine learning
single cell